公开(公告)号：US20100048568A1

公开(公告)日：2010-02-25

申请号：US12570355

申请日：2009-09-30

申请人： Suzanne C. Aldous ,  Michael W. Fennie ,  John Z. Jiang ,  Stanly John ,  Lan Mu ,  Brian Pedgrift ,  James R. Pribish ,  Barbara Rauckman ,  Jeffrey S. Sabol ,  Grzegorz T. Stoklosa ,  Sukanthini Thurairatnam ,  Christopher L. Vandeusen

发明人： Suzanne C. Aldous ,  Michael W. Fennie ,  John Z. Jiang ,  Stanly John ,  Lan Mu ,  Brian Pedgrift ,  James R. Pribish ,  Barbara Rauckman ,  Jeffrey S. Sabol ,  Grzegorz T. Stoklosa ,  Sukanthini Thurairatnam ,  Christopher L. Vandeusen

IPC分类号： A61K31/5377 ,  C07D401/14 ,  A61K31/506 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  A61P11/06 ,  A61P11/00 ,  C07D403/12 ,  A61K31/496 ,  C07D413/14 ,  A61K31/53 ,  C07D417/14 ,  C07D403/14

CPC分类号： C07D239/28 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D417/14

摘要： This invention is directed to a compound of formula (I): wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

摘要翻译： 本发明涉及式（I）化合物：其中R 1，R 2，R 3，R 4和L 1如本文所定义，包含该化合物的药物组合物和该化合物用于治疗过敏和/或炎症性疾病的用途， 尤其是过敏性鼻炎，哮喘和/或慢性阻塞性肺病（COPD）等疾病。

公开(公告)号：US06445850B1

公开(公告)日：2002-09-03

申请号：US09829412

申请日：2001-04-09

申请人： Jianying Zhou ,  Richard A. Barry ,  Murat Azizoglu ,  Derek Spock ,  John Z. Jiang

发明人： Jianying Zhou ,  Richard A. Barry ,  Murat Azizoglu ,  Derek Spock ,  John Z. Jiang

IPC分类号： G02B628

CPC分类号： H04J14/02 ,  H04J14/0213

摘要： A high speed DWDM optical transmission system that reduces a fiber dispersion limit without reducing the total channel count of a multi-wavelength optical signal. The system achieves such reduction in the fiber dispersion limit by employing a multi-wavelength optical signal comprising a gap-free band structure, and performing per-band dispersion compensation on the optical signal by adjusting residual dispersion values associated with one or more of the bands. In one embodiment, the system includes a first dispersion compensation module (DCM) that provides a dispersion-compensated multi-wavelength optical signal containing wavelength-dependent residual dispersion to a band splitter. The band splitter separates the dispersion-compensated optical signal into a plurality of bands such that no band gaps are formed between adjacent bands, and provides each band to a respective second DCM configured to reduce the residual dispersion associated with that band to a predetermined range of residual dispersion values.

公开(公告)号：US07612075B2

公开(公告)日：2009-11-03

申请号：US10628093

申请日：2003-07-25

申请人： William R. Ewing ,  Michael R. Becker ,  Yong Mi Choi-Sledeski ,  Heinz W. Pauls ,  Wei He ,  Stephen M. Condon ,  Roderick S. Davis ,  Barbara A. Hanney ,  Alfred P. Spada ,  Christopher J. Burns ,  John Z. Jiang ,  Michael R. Myers ,  Wan F. Lau ,  Aiwen Li ,  Gregory B. Poli ,  Mark A. Bobko ,  Robert L. Morris ,  Joseph M. Karpinski ,  Timothy F. Gallagher ,  Kent W. Neuenschwander ,  Robert D. Groneberg ,  Jean-Francois Sabuco

发明人： William R. Ewing ,  Michael R. Becker ,  Yong Mi Choi-Sledeski ,  Heinz W. Pauls ,  Wei He ,  Stephen M. Condon ,  Roderick S. Davis ,  Barbara A. Hanney ,  Alfred P. Spada ,  Christopher J. Burns ,  John Z. Jiang ,  Michael R. Myers ,  Wan F. Lau ,  Aiwen Li ,  Gregory B. Poli ,  Mark A. Bobko ,  Robert L. Morris ,  Joseph M. Karpinski ,  Timothy F. Gallagher ,  Kent W. Neuenschwander ,  Robert D. Groneberg ,  Jean-Francois Sabuco

IPC分类号： A61K31/497 ,  C07D401/06

CPC分类号： C07D471/04 ,  C07D241/08 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D495/04

摘要： This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

摘要翻译： 本发明涉及将因子Xa，抑制因子Xa和因子IIa的含氮杂环化合物，包含这些化合物的药物组合物，可用于制备这些化合物的中间体，抑制因子Xa和直接抑制因子Xa的方法的含氮杂环化合物 同时直接抑制因子Xa和因子IIa的方法。

公开(公告)号：US08173682B2

公开(公告)日：2012-05-08

申请号：US11535127

申请日：2006-09-26

申请人： Philip M. Weintraub ,  Paul R. Eastwood ,  Shujaath Mehdi ,  David W. Stefany ,  Kwon Yon Musick ,  Neil Moorcroft ,  Sungtaek Lim ,  John Z. Jiang ,  Hartmut Rutten ,  Stefan Peukert ,  Uwe Schwahn

发明人： Philip M. Weintraub ,  Paul R. Eastwood ,  Shujaath Mehdi ,  David W. Stefany ,  Kwon Yon Musick ,  Neil Moorcroft ,  Sungtaek Lim ,  John Z. Jiang ,  Hartmut Rutten ,  Stefan Peukert ,  Uwe Schwahn

IPC分类号： A61K31/4436 ,  C07D401/14

CPC分类号： C07D213/64 ,  C07D217/24 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14

摘要： The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

摘要翻译： 本发明涉及一系列式I的2,3,5-取代吡啶酮衍生物：其中R，R 1，R 2，R 3和R 4如本文所定义。 本发明还涉及制备这些化合物的方法。 本发明的化合物是聚（腺苷5'-二磷酸核糖）聚合酶（PARP）的抑制剂，因此可用作药剂，特别是用于治疗和/或预防各种疾病，包括与中枢神经相关的疾病 系统和心血管疾病。

公开(公告)号：US07405300B2

公开(公告)日：2008-07-29

申请号：US10933098

申请日：2004-09-01

申请人： John Z. Jiang ,  Jack Roger Koehl ,  Shujaath Mehdi ,  Neil David Moorcroft ,  Kwon Yon Musick ,  Philip Marvin Weintraub ,  Paul Robert Eastwood

发明人： John Z. Jiang ,  Jack Roger Koehl ,  Shujaath Mehdi ,  Neil David Moorcroft ,  Kwon Yon Musick ,  Philip Marvin Weintraub ,  Paul Robert Eastwood

IPC分类号： C07D403/04 ,  C07D209/04

CPC分类号： C04B35/632 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/503 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  C07D209/40 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D471/04 ,  C07D487/08

摘要： The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

摘要翻译： 本发明涉及一系列式I的取代的吲哚衍生物：其中R 1，R 2，R 2，R 3，R 3， X和Y如本文所定义。 本发明还涉及制备这些化合物的方法。 本发明的化合物是聚（腺苷5'-二磷酸核糖）聚合酶（PARP）的抑制剂，因此可用作药剂，特别是用于治疗和/或预防各种疾病，包括与中枢神经相关的疾病 系统和心血管疾病。